PMN310 has been granted Fast Track Designation by the U.S. FDA for the treatment of Alzheimer’s disease.
Investor Relations
Katherine Bock Zafereo
katherine.bock@promisneurosciences.com
Transfer Agent
Computershare Canada
1500 Robert Bourassa Boulevard
7th Floor
Montreal, QC H3A 3S8
Canada
T: 514-982-7502
https://www.computershare.com/ca
Auditor
Baker Tilly US, LLP
Legal Counsel
McMillan LLP
1055 West Georgia St
Suite 1500
Vancouver, BC V6E 4N7
Canada